|1.||Schinazi, R F: 2 articles (07/2005 - 02/2001)|
|2.||Arastèh, K: 1 article (07/2005)|
|3.||Beard, A: 1 article (07/2005)|
|4.||Murphy, R L: 1 article (07/2005)|
|5.||Schulbin, H: 1 article (07/2005)|
|6.||Drauz, D: 1 article (07/2005)|
|7.||Otto, M J: 1 article (07/2005)|
|8.||Kreckel, P: 1 article (07/2005)|
|9.||Herzmann, C: 1 article (07/2005)|
|10.||Cartee, L: 1 article (07/2005)|
07/01/2005 - "Racivir [RCV; (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine], a 50:50 racemic mixture of the two beta nucleoside enantiomers, is currently in development for the treatment of human immunodeficiency virus type 1 (HIV-1) infections. "
02/01/1996 - "HBV replication was equally inhibited in cultures incubated with 524W91 when the drug was added 24 h preinfection, at infection, or 24 h postinfection. "
|2.||Hepatocellular Carcinoma (Hepatoma)
02/01/2001 - "We investigated the replication fitness and susceptibility of the wild-type and five mutant HBVs (L528M, M552I, M552V, L528M/M552I, and L528M/M552V) to 11 compounds [lamivudine, adefovir, entecavir (BMS-200475) (+)-BCH-189 (+/-)-FTC (racivir) (-)-FTC (emtricitabine) (+)-FTC, L-D4FC, L-FMAU (clevudine), D-DAPD, and (-)-carbovir] by transfecting HBV DNA into hepatoma cells and monitoring viral products by Southern blotting. "
|3.||Body Weight (Weight, Body)
|2.||DNA (Deoxyribonucleic Acid)